Your browser doesn't support javascript.
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Bikdeli, Behnood; Madhavan, Mahesh V; Gupta, Aakriti; Jimenez, David; Burton, John R; Der Nigoghossian, Caroline; Chuich, Taylor; Nouri, Shayan Nabavi; Dreyfus, Isaac; Driggin, Elissa; Sethi, Sanjum; Sehgal, Kartik; Chatterjee, Saurav; Ageno, Walter; Madjid, Mohammad; Guo, Yutao; Tang, Liang V; Hu, Yu; Bertoletti, Laurent; Giri, Jay; Cushman, Mary; Quéré, Isabelle; Dimakakos, Evangelos P; Gibson, C Michael; Lippi, Giuseppe; Favaloro, Emmanuel J; Fareed, Jawed; Tafur, Alfonso J; Francese, Dominic P; Batra, Jaya; Falanga, Anna; Clerkin, Kevin J; Uriel, Nir; Kirtane, Ajay; McLintock, Claire; Hunt, Beverley J; Spyropoulos, Alex C; Barnes, Geoffrey D; Eikelboom, John W; Weinberg, Ido; Schulman, Sam; Carrier, Marc; Piazza, Gregory; Beckman, Joshua A; Leon, Martin B; Stone, Gregg W; Rosenkranz, Stephan; Goldhaber, Samuel Z; Parikh, Sahil A; Monreal, Manuel.
  • Bikdeli B; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Madhavan MV; Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, United States.
  • Gupta A; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Jimenez D; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Burton JR; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Der Nigoghossian C; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Chuich T; Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, United States.
  • Nouri SN; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Dreyfus I; Respiratory Department, Hospital Ramón y Cajal, Madrid, Spain.
  • Driggin E; Medicine Department, Universidad de Alcalá (IRYCIS), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
  • Sethi S; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Sehgal K; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Chatterjee S; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Ageno W; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Madjid M; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Guo Y; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Tang LV; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Hu Y; Harvard Medical School, Boston, Massachusetts, United States.
  • Bertoletti L; Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.
  • Giri J; North Shore and Long Island Jewish University Hospitals, Queens, New York, United States.
  • Cushman M; Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • Quéré I; McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, United States.
  • Dimakakos EP; Department of Cardiology, Chinese PLA General Hospital, Beijing, China.
  • Gibson CM; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
  • Lippi G; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Favaloro EJ; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Fareed J; Department of "Médecine Vasculaire et Thérapeutique," CIC 1408, INNOVTE, CHU de St-Etienne and INSERM UMR1059, Université Jean-Monnet, Saint-Etienne, France.
  • Tafur AJ; Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States.
  • Francese DP; Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
  • Batra J; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States.
  • Falanga A; Larner College of Medicine, University of Vermont, Burlington, Vermont, United States.
  • Clerkin KJ; Department of Vascular Medicine, University of Montpellier, Montpellier CHU, InnoVTE F-CRIN Network, Montpellier, France.
  • Uriel N; Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, Athens, Greece.
  • Kirtane A; Harvard Medical School, Boston, Massachusetts, United States.
  • McLintock C; Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.
  • Hunt BJ; Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy.
  • Spyropoulos AC; Laboratory Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.
  • Barnes GD; Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia.
  • Eikelboom JW; Loyola University Medical Center, Chicago, Illinois, United States.
  • Weinberg I; Pritzker School of Medicine at the University of Chicago, Chicago, Illinois, United States.
  • Schulman S; Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois, United States.
  • Carrier M; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Piazza G; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Beckman JA; Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy.
  • Leon MB; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Stone GW; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Rosenkranz S; New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.
  • Goldhaber SZ; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.
  • Parikh SA; Auckland City Hospital, Auckland, New Zealand.
  • Monreal M; St Thomas' Hospital, London, United Kingdom.
Thromb Haemost ; 120(7): 1004-1024, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-418767
ABSTRACT
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Thrombosis / Coronavirus Infections / Fibrinolytic Agents / Inflammation Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Animals / Humans Language: English Journal: Thromb Haemost Year: 2020 Document Type: Article Affiliation country: S-0040-1713152

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Thrombosis / Coronavirus Infections / Fibrinolytic Agents / Inflammation Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Animals / Humans Language: English Journal: Thromb Haemost Year: 2020 Document Type: Article Affiliation country: S-0040-1713152